Published in J Clin Psychiatry on June 01, 2013
Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry (2015) 1.22
Revisiting the discussion: termination of clozapine treatment due to renal failure. J Clin Psychiatry (2015) 1.05
Clozapine Monitoring in Clinical Practice: Beyond the Mandatory Requirement. Clin Psychopharmacol Neurosci (2016) 0.87
The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review. Psychopharmacology (Berl) (2015) 0.86
Double-blind, randomized, clinical trial of metformin as add-on treatment with clozapine in treatment of schizophrenia disorder. J Res Med Sci (2015) 0.85
The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach. Psychopharmacology (Berl) (2015) 0.81
Acute administration of Δ⁹ tetrahydrocannabinol does not prevent enhancement of sensory gating by clozapine in DBA/2 mice. Pharmacol Biochem Behav (2014) 0.80
Factors predicting use of laxatives in outpatients stabilized on clozapine. Ther Adv Psychopharmacol (2015) 0.78
Clozapine prescribing in the UK: views and experience of consultant psychiatrists. Ther Adv Psychopharmacol (2015) 0.78
Predictors of type 2 diabetes in a nationally representative sample of adults with psychosis. World Psychiatry (2014) 0.78
Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports. Psychopharmacology (Berl) (2016) 0.76
Use of antipsychotics increases the risk of fracture: a systematic review and meta-analysis. Osteoporos Int (2017) 0.76
Eosinophilic myocarditis during treatment with olanzapine - report of two possible cases. BMC Psychiatry (2016) 0.75
Dr Nielsen and colleagues reply. J Clin Psychiatry (2015) 0.75
Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future. Curr Top Med Chem (2016) 0.75
Clozapine induced eosinophilia: An often neglected important adverse effect. Indian J Psychiatry (2016) 0.75
Tachycardia in patients treated with clozapine versus antipsychotic long-acting injections. Int Clin Psychopharmacol (2017) 0.75
Rapid-onset clozapine-induced loss of glycaemic control: case report. BJPsych Open (2017) 0.75
Hepatotoxicity induced by clozapine: a case report and review of literature. Neuropsychiatr Dis Treat (2014) 0.75
Actively Negotiating the Mind-Body Divide: How Clozapine-Treated Schizophrenia Patients Make Health for Themselves. Cult Med Psychiatry (2017) 0.75
Clozapine-induced, dilated cardiomyopathy: a case report. BMC Res Notes (2017) 0.75
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA (2009) 6.91
Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry (2005) 6.27
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry (2011) 5.46
Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res (2011) 4.22
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry (2004) 3.59
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry (2007) 3.26
Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry (2003) 3.18
Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol (2007) 2.99
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol (2009) 2.88
What does the PANSS mean? Schizophr Res (2005) 2.86
Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. Am J Psychiatry (2014) 2.81
Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia. Proc Natl Acad Sci U S A (2007) 2.81
Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry (2011) 2.75
Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am J Hum Genet (2004) 2.71
The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr Bull (2003) 2.67
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol (2006) 2.60
Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry (2010) 2.57
National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry (2012) 2.52
Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry (2005) 2.38
Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry (2013) 2.34
Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull (2012) 2.30
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol (2011) 2.15
The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry (2003) 2.15
Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. Bipolar Disord (2013) 2.07
Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull (2008) 1.93
Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol (2011) 1.86
Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.82
Attention-deficit/hyperactivity disorder: a preliminary diffusion tensor imaging study. Biol Psychiatry (2005) 1.80
Tardive dyskinesia circa 2006. Am J Psychiatry (2006) 1.78
Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry (2013) 1.76
Wide excision or Mohs micrographic surgery for the treatment of primary dermatofibrosarcoma protuberans. Am J Clin Oncol (2010) 1.72
The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder. Eur Arch Psychiatry Clin Neurosci (2012) 1.70
Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia. Neuropsychopharmacology (2007) 1.70
Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res (2012) 1.68
Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry (2007) 1.67
Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology (2010) 1.67
Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology (2006) 1.66
Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry (2010) 1.65
Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res (2006) 1.65
Metabolic effects of treatment with atypical antipsychotics. J Clin Psychiatry (2004) 1.63
Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol (2011) 1.63
Obesity and coronary risk in patients treated with second-generation antipsychotics. Eur Arch Psychiatry Clin Neurosci (2010) 1.61
Genetic variation in DTNBP1 influences general cognitive ability. Hum Mol Genet (2006) 1.61
Association of genetic variation in the MET proto-oncogene with schizophrenia and general cognitive ability. Am J Psychiatry (2010) 1.58
Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry (2006) 1.57
Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res (2012) 1.56
White matter abnormalities in first-episode schizophrenia or schizoaffective disorder: a diffusion tensor imaging study. Am J Psychiatry (2005) 1.56
Patterns of stress in schizophrenia. Psychiatry Res (2008) 1.55
Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology (2010) 1.54
Sudden deaths in psychiatric patients. J Clin Psychiatry (2011) 1.53
Are antipsychotics effective for the treatment of anorexia nervosa? Results from a systematic review and meta-analysis. J Clin Psychiatry (2012) 1.52
Progressive muscle relaxation in persons with schizophrenia: a systematic review of randomized controlled trials. Clin Rehabil (2012) 1.51
Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry (2014) 1.50
Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry (2003) 1.49
Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry (2005) 1.49
Clozapine as a first treatment for schizophrenia. Am J Psychiatry (2003) 1.49
Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr Res (2004) 1.49
Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology (2010) 1.47
Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry (2003) 1.47
Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes. Br J Psychiatry (2009) 1.47
Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia. J Clin Psychopharmacol (2008) 1.46
Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry (2007) 1.45
Association of the DTNBP1 locus with schizophrenia in a U.S. population. Am J Hum Genet (2004) 1.45
Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res (2008) 1.45
Cognitive development in schizophrenia: follow-back from the first episode. J Clin Exp Neuropsychol (2006) 1.42
DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry (2006) 1.41
A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg (2009) 1.39
Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long? Am J Psychiatry (2013) 1.39
The assessment of "prodromal schizophrenia": unresolved issues and future directions. Schizophr Bull (2003) 1.36
Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia. Biol Psychiatry (2006) 1.34
Soft tissue sarcoma. J Natl Compr Canc Netw (2010) 1.34
Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology (2007) 1.34
Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry (2009) 1.33
Impact of neurocognition on social and role functioning in individuals at clinical high risk for psychosis. Am J Psychiatry (2011) 1.28
Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection. Schizophr Res (2005) 1.27
Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology (2007) 1.27
Personal stigma in schizophrenia spectrum disorders: a systematic review of prevalence rates, correlates, impact and interventions. World Psychiatry (2013) 1.27
Reduced frontal white matter integrity in early-onset schizophrenia: a preliminary study. Biol Psychiatry (2004) 1.26
Differentiation in the preonset phases of schizophrenia and mood disorders: evidence in support of a bipolar mania prodrome. Schizophr Bull (2007) 1.26
Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol (2012) 1.25
In silico and in vivo approach to elucidate the inflammatory complexity of CD14-deficient mice. Mol Med (2006) 1.25
The validity of the schizophrenia diagnosis in the Danish Psychiatric Central Research Register is good. Dan Med J (2013) 1.25
Genome-wide association study implicates NDST3 in schizophrenia and bipolar disorder. Nat Commun (2013) 1.25
Strategies for mHealth research: lessons from 3 mobile intervention studies. Adm Policy Ment Health (2015) 1.25
Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry (2007) 1.24
Sex differences in frontal lobe white matter microstructure: a DTI study. Neuroreport (2003) 1.23
White matter abnormalities in early-onset schizophrenia: a voxel-based diffusion tensor imaging study. J Am Acad Child Adolesc Psychiatry (2005) 1.23